Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S.
Journal of Law, Medicine & Ethics · 2023
DOI: 10.1017/jme.2023.76 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, 2023. Verfasst von Liam Bendicksen und 1 weiteren Autor:innen. Beteiligte Einrichtung: PORTAL, BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA, USA. Hauptthemen laut MEDLINE: Abortion, Induced, Prescription Drugs.
Abstract (Originalsprache)
Legal challenges to the FDA’s approval of mifepristone have destabilized patients’ ability to access controversial medicines like medication abortion. We argue that federal courts’ receptiveness to this litigation undermines the coherence and integrity of prescription drug regulation in the U.S.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PORTAL, BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA, USA.
- HARVARD MEDICAL SCHOOL, BOSTON, MA, USA.
ORCID-Profile: Liam Bendicksen
Zitieren
APA
Bendicksen, L., & Kesselheim, A. S. (2023). Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S. Journal of Law, Medicine & Ethics. https://doi.org/10.1017/jme.2023.76
Vancouver
Bendicksen L, Kesselheim AS. Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S. Journal of Law, Medicine & Ethics. 2023. doi:10.1017/jme.2023.76
BibTeX
@article{Bendicksen2023,
author = {Bendicksen, Liam and Kesselheim, Aaron S},
title = {Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S},
journal = {Journal of Law, Medicine & Ethics},
year = {2023},
doi = {10.1017/jme.2023.76}
}
EUVIMED